A practical reference on Melanotan II: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-01-08 and is reviewed periodically as new material appears.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
Activity is attributed to agonism at melanocortin receptors, particularly MC1R and MC4R. Activation of MC1R on melanocytes increases melanin synthesis, which underlies the reported tanning effect. MC4R engagement in the central nervous system is linked to appetite suppression and to effects on sexual arousal reported in early clinical studies. Those studies were small and were not designed to establish efficacy or long-term safety. Receptor selectivity among the melanocortin subtypes is not absolute, which complicates attribution of any effect to a single pathway.
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic cyclic heptapeptide | Analogue of alpha-melanocyte-stimulating hormone |
| Common synonyms | MT-II; melanotan 2 | No internationally accepted non-proprietary name |
| Typical presentation | Lyophilised powder in a sealed vial | Often supplied alongside a separate diluent |
| Regulatory status | Unapproved therapeutic substance | Customs seizure reported in several jurisdictions |
| Reported route in use | Subcutaneous injection | Self-administered outside clinical settings |
=== Incel slang === Clavicular is primarily recognized for introducing language and slang from the incelosphere and manosphere to mainstream society. Peters transformed quickly from an "obscure online presence" into one of the internet's "most inescapable figures" by transforming "chaos into content" and running it through his various "clip accounts". Miami New Times says, "His traditionally handsome face and natural charisma, punctuated by increasingly bizarre moments that feel distinctly internet-era, have turned him into one of livestreaming's most compulsively watchable figures." NBC's Saturday Night Live mocks him, CBS's 60 Minutes interviews him (as does Sean Hannity). The New York Times profiled him and the Hulu looksmaxxing documentary "IMPACT x Nightline: Looksmaxxed" focuses on him. Lingo Peters popularizes has "seeped into the public consciousness" with slang words like "mogging" and the suffix "maxxing" gaining widespread use.
He worked as a music journalist and ran a magazine publishing business, launching Flexipop magazine in 1980 with ex-Record Mirror journalist Barry Cain. Robin Lustig (born 30 August 1948, London); was foreign correspondent in Madrid for Reuters; worked for The Observer as editor and Middle East correspondent; also presented The World Tonight, Newsstand, Stop Press, and File on 4 for Radio 4, and Newshour on the BBC World Service; presented programme covering sudden death of Diana, Princess of Wales, hours after announcement was made; also presented Talking Point (later renamed Have Your Say) for BBC World Service, BBC World TV; guests included Nelson Mandela, Thabo Mbeki, Olusegun Obasanjo, Hugo Chávez and Tony Blair; later worked on The World Tonight and Newshour; for BBC World Service, has presented every UK election night programme since 1997 as well as United States presidential election programmes; reported on elections in Iran, Israel, Japan, Russia and Zimbabwe; presented The World Tonight from Afghanistan, China, Iran, Iraq, Japan, Kosovo and Mexico; was awarded Gold Medal at the New York Radio Festival and broadcast live from Moscow on last day of Soviet Union; in 1998, won Sony Silver Award; was described in The Times as "arguably the best news presenter anywhere in radio after John Humphrys"; received Charles Wheeler award for outstanding contribution to broadcast journalism.
=== Bacteria === Necrotizing fasciitis is classified into four groups based on the type of bacteria causing the infection. This classification system was first described by Giuliano and his colleagues in 1977. Type I infection: This is the most common type of infection, and accounts for 70–80% of cases. It is caused by a mixture of bacterial types, usually in the abdominal or groin areas. These bacterial species include:
Sources: en.wikipedia.org
=== Pirkle-type CSP === Pirkle and co-workers pioneered the development of a variety of CSPs based on charge-transfer complexation and simultaneous hydrogen bonding. These phases are also referred to as Brush-type CSPs. The Pirkle phases are based on aromatic π-acid (3,5-dinitrobenzoyI ring) and π- basic (naphthalene) derivative. In addition to π-π interaction sites, they have hydrogen-bonding and dipole-dipole interaction sites provided by an amide, urea or ester functionality. Strong three-point interaction, according to Dalgleish's model, enables enantioseparation. These phases are classified into π-electron-acceptor, π-electron-donor or π-electron acceptor-donor phase. A number of Pirkle-type CSPs are commercially available. They are used most often in the normal phase mode. The ionic form of the DNPBG (3,5-dinitrobenzoyl-phenylglycine) CSP has been successfully employed to achieve separation of racemic propranolol in biological fluid. Many compounds of pharmaceutical interest including enantiomers of naproxen and metoprolol has been separated using Pirkle CSP.
=== High-altitude radiation === In 1912, Victor Franz Hess (1883-1964) discovered (secondary) cosmic rays in the Earth's atmosphere using balloon flights. For this discovery he received the Nobel Prize in Physics in 1936. He was also one of the "martyrs" of early radiation research and had to undergo a thumb amputation and larynx surgery due to radium burns. In the United States and the Soviet Union, balloon flights to altitudes of about 30 km, followed by parachute jumps from the stratosphere, were conducted before 1960 to study human exposure to cosmic radiation in space. The American Manhigh and Excelsior projects with Joseph Kittinger (1928-2022) became particularly well known, but the Soviet parachutist Yevgeny Andreyev (1926-2000) also set new records.
=== Inhibition of ACTH production === Corticotropes contain glucocorticoid receptors (GRs) and corticosteroid-binding globulin (CBG, or transcortin). GR is a nuclear receptor that inhibits transcription of ACTH via a negative glucocorticoid recognition element (GRE) that binds cortisol on POMC DNA, but generally transcortin binds glucocorticoids (including cortisol, cortisone, deoxycortisone, and aldosterone) with high affinity and prevents this inhibition. Tonic inhibition of corticotropes requires high concentrations of glucocorticoids, exceeding CBG capacity. This causes ACTH secretion to be vulnerable to inhibition in patients taking glucocorticoids for medical purposes such as treatment of autoimmune disease or as an anti-transplant-rejection medication.
Sources: en.wikipedia.org
=== Lifestyle === Weight loss is the most effective treatment for MASLD and MASH. A loss of 5% to 10% body weight is recommended and has shown regression of liver damage, with 10% to 40% weight loss completely reversing MASH without cirrhosis. A weight loss of greater than 10% was associated with the resolution of MASH in 90% of people in a biopsy-based study. A structured weight loss program helps people with MASLD lose more weight compared with advice alone. This type of program also leads to improvements in MASLD measured by blood tests, ultrasound, imaging, or liver biopsies. Although fibrosis improves with lifestyle interventions and weight loss, there is limited evidence for improvement in cirrhosis. A combination of improved diet and exercise, rather than either alone, appears to help manage MASFLD and reduce insulin resistance. Motivational support, such as with cognitive behavioral therapy, is helpful, as most people with MASLD do not perceive their condition as a disease, and thus have a low motivation to change. Higher-intensity behavioral weight loss therapies (diet and exercise combined) may produce greater weight loss than lower-intensity ones. A 2019 systematic review suggested updating the guidelines to recommend these therapies for MASLD management. Weight loss is associated with improvements in biomarkers, MASLD severity, and a lower risk of MASH, but its effect on long-term health is not known.
== Research == Trazodone may be effective in the treatment of sexual dysfunction, for instance female sexual dysfunction and erectile dysfunction. A 2003 systematic review and meta-analysis found some indication that trazodone may be useful in the treatment of erectile dysfunction. Besides trazodone alone, a combination of trazodone and bupropion (developmental code names and tentative brand names S1P-104, S1P-205, Lorexys, and Orexa) is under development for the treatment of erectile dysfunction and female sexual dysfunction. As of September 2021, it is in phase 2 clinical trials for these indications. It has been in this stage of clinical development since at least February 2015. Trazodone may be useful in the treatment of certain symptoms like sleep disturbances in alcohol withdrawal and recovery. However, reviews have recommended against use of trazodone for alcohol withdrawal due to inadequate evidence. Very limited evidence suggests that trazodone might be useful in the treatment of certain symptoms in cocaine use disorder. Trazodone has been reported to be effective in the treatment of sleep apnea. Cochrane reviews found that trazodone was not effective in the treatment of agitation in dementia. Another Cochrane review found that trazodone might be useful in the treatment of sleep disturbances in dementia. Further systematic reviews have found that trazodone may be effective for behavioral and psychological symptoms in dementias such as frontotemporal dementia and Alzheimer's disease.
Cardiovascular: dyslipidemia (e.g., increased LDLTooltip low-density lipoprotein levels, decreased HDLTooltip high-density lipoprotein levels, reduced apo-A1Tooltip apolipoprotein A1 levels), atherosclerosis, elevated hematocrit, hypertension, left ventricular hypertrophy, cardiomyopathy, myocardial hypertrophy, polycythemia/erythrocytosis, arrhythmias, thrombosis (e.g., embolism, stroke), myocardial infarction, sudden death. Hepatic: elevated liver function tests (ASTTooltip aspartate aminotransferase, ALTTooltip alanine aminotransferase, bilirubin, LDHTooltip lactic dehydrogenase, ALPTooltip alkaline phosphatase), hepatotoxicity, jaundice, hepatic steatosis, hepatocellular adenoma, hepatocellular carcinoma, cholestasis, peliosis hepatis; all mostly or exclusively with 17α-alkylated AAS. Renal: renal hypertrophy, nephropathy, acute renal failure (secondary to rhabdomyolysis), focal segmental glomerulosclerosis, renal cell carcinoma. Others: glucose intolerance, insulin resistance, immune dysfunction.
In 2022, the COSMIC confidence score was added to the CSI:FingerID structure identification workflow in SIRIUS 4, allowing users to determine the trustworthiness of the identification. In 2024, the de novo generation of candidate structures through MSNovelist was introduced with SIRIUS 6.
Sources: en.wikipedia.org
No. No major regulatory agency has granted a marketing authorisation for melanotan II as a medicine. Products sold under this name are generally presented as laboratory reagents and are not subject to the batch-release testing applied to approved drugs.
It was developed in the 1980s by researchers investigating analogues of alpha-melanocyte-stimulating hormone for pigmentation and related endpoints. Early work included small human studies during the 1990s. Development did not progress to licensing, and the compound remained a research and grey-market item.
Peptides are prone to truncation, oxidation and aggregation during synthesis and handling. Without independent testing, a buyer cannot confirm the identity or the content of a vial. Analytical surveys of unapproved peptide products have repeatedly found discrepancies between label claims and measured composition.
It is a synthetic cyclic heptapeptide and a non-selective melanocortin receptor agonist. Structurally it is modelled on alpha-melanocyte-stimulating hormone, a peptide that occurs naturally in the body.